Head and Neck Cancer Market Research Report - Forecast to 2027

Head and Neck Cancer Market Research Report: By type (Laryngeal, Pharyngeal, Salivary Gland, Oral Cavity, Nasopharyngeal), by Diagnosis (Blood Test, Endoscopy, others), by Treatment (Chemotherapy, Surgery, Others), by End-User – Global Forecast Till 2027

ID: MRFR/MED/4342-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario


Head and neck cancer begins in squamous cells that line the mucosal surfaces of the head and neck such as, inside the mouth, the nose, and the throat. The head and neck cancers include specific areas of the body such as oral cavity, pharynx, larynx, paranasal sinuses and nasal cavity, and salivary glands. Alcohol and tobacco are the two most common risk factors for head and neck cancers. Other risk factors for head and neck cancers include consumption of preserved or salted foods, occupational exposure to wood dust, Epstein-Barr virus infection, and poor oral hygiene.


It is noted that the rising prevalence of head and neck cancers is the key factor driving the head and neck cancer market. According to the 2014 statistics suggested by the World Health Organization (WHO), the annual occurrence rate of head and neck cancer is more than 550,000 cases with nearly 300,000 deaths each year, worldwide. Around 90% of the head and neck cancers are squamous cell carcinomas, and they are also the sixth leading cancer by occurrence worldwide.


In the United States, the head and neck cancer accounts for 3% of malignancies, i.e., around 63,000 Americans developing head and neck cancer annually, and 13,000 dying of this disease. In Europe, there were approximately 250,000 cases of cancer registered and 63,500 deaths in 2012.


Various other factors such as growing geriatric population, huge research funding in oncology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance are continuously contributing to the growth of the global head and neck cancer market.


According to a study published in the Cancer and Metastasis Reviews in 2017, the risk for head and neck squamous cell carcinoma in smokers is nearly ten times higher than that of non-smokers, and the diagnosis of 70 to 80% of new head and neck squamous cells is associated with the consumption tobacco and alcohol.


Despite these drivers, there are some issues associated with the head and neck cancer market. The high cost associated with treatment approach, side effects of available treatment options, lack of healthcare coverage, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.


It is Estimated that the Head and Neck Cancer Market is expected to grow at a CAGR of 9.5% during the forecast period of 2017–2023.


Research Methodology


 Head and Neck Cancer Market


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience



  • Pharmaceutical Companies

  • Oncology Associations

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institutes

  • Academic Institutes and Universities


Segmentation


The global head and neck cancer market is segmented on the basis of the type of head and neck cancer, diagnosis, treatment type, and end-user.


On the basis of the type of head and neck cancer, the market is classified as laryngeal cancer, pharyngeal cancer, salivary gland cancer, lip and oral cavity cancer, nasopharyngeal cancer, and others.


On the basis of diagnosis, the market is classified as bioscopy screening tests, blood tests, dental diagnosis, imaging, and endoscopy. The bioscopy screening tests are further classified as incisional biopsy, fine needle aspiration biopsy, and HPV testing. The blood tests are further classified as total cell count tests, liver function tests, and EBV antibody measurement. The dental diagnosis is further classified as fluorescence visualization, toluidine blue dye-based method, acetic acid rinse method, and brush biopsy. The imaging is further classified as PET/CT, MRI, X-ray, and Barium Swallow test. The endoscopy is further classified as pharyngoscopy, laryngoscopy, and others.


On the basis of treatment type, the market is classified as chemotherapy, surgery, radiation therapy, targeted therapy, and others. The radiation therapy is further classified as external beam radiation and internal radiation therapy.


On the basis of end-user, the market is classified as hospitals, specialty clinics, and ambulatory surgical centers.


Regional Analysis


The Americas dominate the head and neck cancer market owing to the presence of patient population, increasing prevalence of head and neck cancer, well-developed technology, high healthcare expenditure, and the presence of leading market players. The head and neck cancer accounts for nearly 3% of all the cancers in the United States. In 2017, around 63,030 people developed head and neck cancer.


Europe holds the second position in the head and neck cancer market. It is expected that the research and development expenditure provided by the government and private associations, increasing competition among marketers, rising healthcare expenditure, and amendments in reimbursement policies in healthcare are likely to drive the European head and neck cancer market.


Asia Pacific is the fastest growing head and neck cancer market owing to a huge patient pool, increasing demand, and development of the healthcare technology.


The Middle East and Africa holds the lowest share of the global head and neck cancer market due to low development, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global head and neck cancer market are AB Science SA, AbbVie Inc., Acceleron Pharma, Inc., AdDent Inc., ASAHI Roentgen, Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Carestream, Fujifilm Holdings, GE Healthcare, Identafi, Koninklijke Philips N.V., NeuSoft, Shimadzu Corporation, Siemens Healthcare, Varian Medical Systems, Xoran, and others.



Frequently Asked Questions (FAQ) :


Major types of head and neck cancer include salivary gland, laryngeal, pharyngeal, oral cavity, and nasopharyngeal.

Global Head and Neck Cancer Market is expected to exhibit a strong 9.5% CAGR over the forecast period from 2017 to 2023.

Growing awareness about cancer is the major driver for the Head and Neck Cancer Market.

The Americas dominate the Global Head and Neck Cancer Market.

Leading players in the Head and Neck Cancer Market include AbbVie, Boston Biomedical, and Bayer AG, among others.

Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Head & Neck Cancer Market, By Type

6.1 Introduction

6.2 Laryngeal Cancer

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Pharyngeal Cancer

6.3.1 Market Estimates & Forecast, 2020–2027

6.4 Salivary Gland Cancer

6.4.1 Market Estimates & Forecast, 2020–2027

6.5 Lip & Oral Cavity Cancer

6.5.1 Market Estimates & Forecast, 2020–2027

6.6 Nasopharyngeal Cancer

6.6.1 Market Estimates & Forecast, 2020–2027

6.7 Others

6.7.1 Market Estimates & Forecast, 2020–2027 Chapter 7. Global Head & Neck Cancer Market, By Diagnosis

7.1 Introduction

7.2 Bioscopy Screening Tests

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Blood Tests

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Dental Diagnosis

7.4.1 Market Estimates & Forecast, 2020–2027

7.5 Imaging

7.5.1 Market Estimates & Forecast, 2020–2027

7.6 Endoscopy

7.6.1 Market Estimates & Forecast, 2020–2027 Chapter 8. Global Head & Neck Cancer Market, By Treatment

8.1 Introduction

8.2 Chemotherapy

8.2.1 Market Estimates & Forecast, 2020–2027

8.3 Surgery

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Radiation Therapy

8.4.1 Market Estimates & Forecast, 2020–2027

8.5 Targeted Therapy

8.5.1 Market Estimates & Forecast, 2020–2027

8.6 Others

8.6.1 Market Estimates & Forecast, 2020–2027 Chapter 9. Global Head & Neck Cancer Market, By End-User

9.1 Introduction

9.2 Hospital

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Specialty Clinics

9.3.2 Market Estimates & Forecast, 2020–2027

9.4 Ambulatory Surgical Centers

9.4.1 Market Estimates & Forecast, 2020–2027

9.5 Others

9.5.2 Market Estimates & Forecast, 2020–2027

Chapter 10. Global Head & Neck Cancer Market, By Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest Of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic Of Korea

10.4.6 Rest Of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest Of The Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 AB Science SA

11.1.1 Company Overview

11.1.2 Types Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 AstraZeneca Plc.

11.2.1 Company Overview

11.2.2 Types Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bristol-Myers Squibb Company

11.3.1 Company Overview

11.3.2 Types Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Koninklijke Philips N.V.

11.4.1 Company Overview

11.4.2 Types/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Shimadzu Corporation

11.5.1 Company Overview

11.5.2 Types Overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.6 Siemens Healthcare

11.6.1 Company Overview

11.6.2 Types Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 VARIAN MEDICAL SYSTEMS

11.7.1 Overview

11.7.2 Types Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs Of The Market

12.2 Key Companies To Watch

12.3 Prediction Of The Head & Neck Cancer Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Head & Neck Cancer Industry Synopsis, 2020–2027

Table 2 Head & Neck Cancer Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Head & Neck Cancer Market, By Region, 2020–2027, (USD Million)

Table 4 Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 5 Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 6 Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 7 Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 8 North America Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 9 North America Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 10 North America Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 11 North America Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 12 U.S. Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 13 U.S. Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 14 U.S. Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 15 U.S. Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 16 Canada Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 17 Canada Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 19 Canada Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 20 South America Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 21 South America Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 22 South America Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 23 South America Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 24 Europe Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 25 Europe Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 27 Europe Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 28 Western Europe Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 29 Western Europe Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 33 Eastern Europe Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 37 Asia Pacific Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

Table 40 Middle East & Africa Head & Neck Cancer Market, By Type, 2020–2027, (USD Million)

Table 41 Middle East & Africa Head & Neck Cancer Market, By Diagnosis, 2020–2027, (USD Million)

Table 42 Middle East & Africa Head & Neck Cancer Market, By Treatment, 2020–2027, (USD Million)

Table 43 Middle East & Africa Head & Neck Cancer Market, By End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Head & Neck Cancer Market

Figure 3 Segmentation Market Dynamics For Head & Neck Cancer Market

Figure 4 Global Head & Neck Cancer Market Share, By Type 2020

Figure 5 Global Head & Neck Cancer Market Share, By Diagnosis 2020

Figure 6 Global Head & Neck Cancer Market Share, By Treatment 2020

Figure 7 Global Head & Neck Cancer Market Share, By End-User, 2020

Figure 8 Global Head & Neck Cancer Market Share, By Region, 2020

Figure 9 North America Head & Neck Cancer Market Share, By Country, 2020

Figure 10 Europe Head & Neck Cancer Market Share, By Country, 2020

Figure 11 Asia Pacific Head & Neck Cancer Market Share, By Country, 2020

Figure 12 Middle East & Africa Head & Neck Cancer Market Share, By Country, 2020

Figure 13 Global Head & Neck Cancer Market: Company Share Analysis, 2020 (%)

Figure 14 AB Science SA: Key Financials

Figure 15 AB Science SA Segmental Revenue

Figure 16 AB Science SA: Geographical Revenue

Figure 17 AstraZeneca Plc.: Key Financials

Figure 18 AstraZeneca Plc.: Segmental Revenue

Figure 19 AstraZeneca Plc.: Geographical Revenue

Figure 20 Bristol-Myers Squibb Company: Key Financials

Figure 21 Bristol-Myers Squibb Company: Segmental Revenue

Figure 22 Bristol-Myers Squibb Company: Geographical Revenue

Figure 23 Koninklijke Philips N.V.: Key Financials

Figure 24 Koninklijke Philips N.V.: Segmental Revenue

Figure 25 Koninklijke Philips N.V.: Geographical Revenue

Figure 26 Shimadzu Corporation: Key Financials

Figure 27 Shimadzu Corporation: Segmental Revenue

Figure 28 Shimadzu Corporation Geographical Revenue

Figure 29 Siemens Healthcare: Key Financials

Figure 30 Siemens Healthcare: Segmental Revenue

Figure 31 Siemens Healthcare: Geographical Revenue

Figure 32 VARIAN MEDICAL SYSTEMS: Key Financials

Figure 33 VARIAN MEDICAL SYSTEMS: Segmental Revenue

Figure 34 VARIAN MEDICAL SYSTEMS: Geographical Revenue